GERMICIDAL UV LIGHT SYSTEMS BUSINESS PLAN

I. Executive Summary

Company Description

Company name withheld by founder. Based in a major U.S. metropolitan hub and launching in 2026, we operate in the commercial indoor air quality and disinfection sector. We deliver custom-engineered germicidal UV-C systems for high-traffic indoor environments, pairing technical installations with proprietary software to manage continuous, automated pathogen control. One-liner: We provide engineered UV-C disinfection systems plus software for continuous, automated pathogen control.

Our core activities are designing and installing high-value UV-C hardware, onboarding and training facility teams, and supporting long-term recurring maintenance contracts verified by third-party testing. We target commercial customers in hospitals, transit hubs, education, and multi-tenant buildings. Short-term goals: complete pilot installations and secure multi-year maintenance contracts in 2026–2027. Long-term goals: scale regional deployments, standardize third-party verification, and expand recurring maintenance revenue. One-liner: We combine installation, verified performance, and recurring service to create durable, scalable revenue streams.

Problem

Commercial indoor spaces in the U.S. face persistent, invisible threats from viruses, bacteria, and mold that traditional manual cleaning does not eliminate. Manual sanitation is intermittent and labor‑intensive, leaving protection gaps between cleaning cycles and no reliable way to demonstrate continuous safety to employees, customers, regulators, and insurers.

These gaps increase absenteeism and sick‑leave costs, raise safety concerns, create compliance and liability exposure, and force frequent, costly manual cleaning. Existing methods lack continuous, verifiable disinfection standards and third‑party validation.

Continuous, verifiable disinfection is required to reduce health risk and operational liability.

Based in a major U.S. metropolitan hub and launching in 2026, we provide custom‑engineered UV‑C systems plus recurring maintenance and third‑party verification to close this persistent protection gap.

Solution

Businesses face persistent airborne and surface pathogen risks that manual cleaning cannot eliminate, raising absenteeism and liability in clinics, gyms, offices, and other high-traffic facilities. Our offering delivers advanced UV-C disinfection systems—upper-room germicidal ultraviolet fixtures and in-duct units—installed and calibrated to facility dimensions and airflow to provide continuous, passive pathogen reduction that complements HVAC and cleaning protocols.

We provide site-specific design, professional installation, and scheduled maintenance so facilities have a verifiable, permanent disinfection infrastructure that operates 24/7, maintains target exposure levels, and supports compliance with operating guidelines.

Mission Statement

We protect public health and provide peace of mind by delivering advanced, reliable, and verifiably effective UV-C disinfection solutions for commercial spaces. We are dedicated to technical excellence, safety, and creating healthier indoor environments through innovation and superior service. We strive to be the trusted partner for businesses that prioritize employee and customer well-being, backed by certification and continuous monitoring that set the standard for environmental safety.

Key Success Factors

One-line: Success depends on turning technical UV-C expertise into reliable, scalable service.

• Convert technical expertise into a hassle-free customer experience.
• Maintain Tier-1 UV-C component partnerships for reliable installations.
• Build recurring revenue targeting 90% maintenance-plan allocation by 2030.
• Keep rigorous safety and regulatory compliance to preserve market trust.
• Scale technical team and service fleet in line with regional demand.

Financial Summary

The five-year forecast shows revenue growth from $409,000 in 2026 to $2,769,000 in 2030, with breakeven reached in June 2028.

Financial requirements include a minimum cash cushion of $179,000; breakeven is forecast for Jun-28. Anticipated returns are IRR 0.33 and ROE 0.41, with EBITDA turning positive in 2028 and reaching $741,000 by 2030.

Overall outlook: revenue scale and operational leverage support positive ROI and sustained profitability by year three.

Funding Requirements

We seek $600,000 to buy fleet and equipment, stock inventory, implement specialized software, fund marketing, and maintain a minimum cash buffer to sustain a 5.0 FTE team until mid-2028 breakeven.

Projected revenue grows from $409,000 in Year 1 to $2,769,000 by Year 5; initial EBITDA loss of -$325,000 in 2026, breakeven by June 2028, EBITDA of $741,000 by 2030, IRR 0.33, ROE 0.41, and billable hours per customer reaching 18.0/month by year five.